EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DNA-incorporated thioguanine to detect potential non-adherence to maintenance therapy in acute lymphoblastic leukemia

Mathilde Rønne Koch, Anna Sofie Buhl Rasmussen, Bodil Als-Nielsen, Ximo Duarte, Gabriele Escherich, Mats Heyman, Kristi Lepik, Johan Malmros, Jacob Nersting, Inga Johannsdottir, Riitta Niinimäki, Malene Johanne Petersen und 6 weitere

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-025-04784-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Mathilde Rønne Koch und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Thioguanine, DNA, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Adherence to 6-mercaptopurine (6-MP)/methotrexate maintenance treatment for acute lymphoblastic leukemia (ALL) is pivotal to preventing relapse, and the 6-MP metabolite DNA-incorporated thioguanine (DNA-TG) is associated with relapse risk. In the ALLTogether-1 (A2G1) Maintenance sub-study (EU CT nr 2022-501050-11-01), DNA-TG, thioguanine nucleotides (TGN), and methylated mercaptopurine metabolites (MeMP) are analyzed regularly. Upon levels below preset limits (TGN < 50, or MeMP < 200 or < 100 nmol/mmol hemoglobin for thiopurine S-methyltransferase (TPMT) wild type and heterozygous patients, respectively), the treating physician is informed of potential non-adherence. We investigated the feasibility of using DNA-TG as the primary flagging of potential non-adherence.

Methods

We analyzed 6-MP metabolites in 3,074 blood samples from 368 children enrolled in the A2G1 Maintenance sub-study.

Results

In 6% of samples, TGN (median 212, 95% range 40–642), MeMP (median 4,959, 95% range 135–23,880) or both were below the flagging potential non-adherence limits. DNA-TG was associated with TGN (estimate = 1.72, p < 0.0001), MeMP (estimate = 1.10, p < 0.0001), and prescribed 6-MP dose (estimate = 1.083 and 1.132, p < 0.0001, for TPMT wild type and heterozygous patients) in linear effects models, and the predicted probability of treatment interruption in logistic regression models. DNA-TG was below 200 fmol TG/µg DNA (13th percentile of all measurements, median 569, 95% range 73–1,823) in all samples with both TGN and MeMP below the flagging potential non-adherence limits.

Conclusion

DNA-TG can provide a cost-effective guidance on when to measure TGN and MeMP to determine whether non-adherence should be suspected, which is an additional benefit to monitoring DNA-TG during maintenance therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaThioguanineDNAAntineoplastic Combined Chemotherapy ProtocolsHumansChildMaleFemaleMercaptopurineChild, PreschoolAdolescentMaintenance ChemotherapyAntimetabolites, AntineoplasticMethotrexateInfantMethyltransferases

Stichwörter der Autor:innen

Acute lymphoblastic leukemiaAdherenceDNA thioguanineMaintenance therapyMercaptopurineTherapeutic drug monitoring

Substanzen

ThioguanineMercaptopurineDNAAntimetabolites, AntineoplasticMethotrexateMethyltransferases

Autor:innen und Institutionen

  • Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Departamento de Pediatria, Instituto Português de Oncologia Lisboa Francisco Gentil, Lisbon, Portugal.
  • University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Women's and Children's Health, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
  • Tallinn Children's Hospital, Tallinn, Estonia.
  • Dept of Ped hematology and oncology, Oslo University Hospital, Oslo, Norway.

Förderung

  • National Hospital

Zitieren

APA

Koch, M. R., Buhl Rasmussen, A. S., Als-Nielsen, B., Duarte, X., Escherich, G., Heyman, M., Lepik, K., Malmros, J., Nersting, J., Johannsdottir, I., Niinimäki, R., Petersen, M. J., Segers, H., van der Sluis, I. M., Thastrup, M., Vaitkeviciene, G., Schmiegelow, K., & Toksvang, L. N. (2025). DNA-incorporated thioguanine to detect potential non-adherence to maintenance therapy in acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04784-7

Vancouver

Koch MR, Buhl Rasmussen AS, Als-Nielsen B, Duarte X, Escherich G, Heyman M, et al. DNA-incorporated thioguanine to detect potential non-adherence to maintenance therapy in acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04784-7

BibTeX
@article{Koch2025,
  author = {Koch, Mathilde Rønne and Buhl Rasmussen, Anna Sofie and Als-Nielsen, Bodil and Duarte, Ximo and Escherich, Gabriele and Heyman, Mats and Lepik, Kristi and Malmros, Johan and Nersting, Jacob and Johannsdottir, Inga and Niinimäki, Riitta and Petersen, Malene Johanne and Segers, Heidi and van der Sluis, Inge Margriet and Thastrup, Maria and Vaitkeviciene, Goda and Schmiegelow, Kjeld and Toksvang, Linea Natalie},
  title = {DNA-incorporated thioguanine to detect potential non-adherence to maintenance therapy in acute lymphoblastic leukemia},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-025-04784-7}
}
Kostenlos starten →